Alfresa Lifts Earnings, Keeps Guidance and Raises Dividend Despite Margin Pressure

Alfresa Holdings ( (JP:2784) ) just unveiled an update.

Alfresa Holdings reported consolidated net sales of ¥2.36 trillion for the nine months ended December 31, 2025, up 4.5% year on year, while operating and ordinary profit declined slightly, but profit attributable to owners of parent jumped 24.3% to ¥31.98 billion, supported by higher earnings per share as the share count fell. The company’s total assets rose to ¥1.63 trillion and net assets to ¥497.09 billion, and it maintained its full-year forecast, projecting modest sales growth but slightly lower profits, while planning to raise annual dividends to ¥68 per share, signaling continued shareholder returns despite profit margin pressure.

For the fiscal year ending March 31, 2026, Alfresa expects net sales of ¥3.11 trillion with operating profit of ¥37.1 billion and profit attributable to owners of parent of ¥36 billion, a 31.4% increase, indicating confidence in earnings expansion despite cost headwinds. The equity ratio dipped to 30.5% from 33.5%, suggesting a more asset-heavy balance sheet, but steady dividend growth and unchanged guidance underscore management’s stable outlook for its role in Japan’s pharmaceutical distribution sector.

The most recent analyst rating on (JP:2784) stock is a Buy with a Yen2650.00 price target. To see the full list of analyst forecasts on Alfresa Holdings stock, see the JP:2784 Stock Forecast page.

More about Alfresa Holdings

Alfresa Holdings Corporation is a Japan-based company operating in the pharmaceutical distribution and healthcare-related services industry. Listed on the Prime Market of the Tokyo Stock Exchange, it focuses on nationwide wholesale distribution of pharmaceuticals and medical products, serving healthcare institutions across Japan as a core part of the medical supply chain.

Average Trading Volume: 294,195

Technical Sentiment Signal: Buy

Current Market Cap: Yen485.1B

For detailed information about 2784 stock, go to TipRanks’ Stock Analysis page.